Physician profile
Heminder Singh
NPI 1659407799
$2,585.84
in general payments reported to CMS, 2019-2025
11 companies · $728 in 2025
The $728 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.08 · 2020: $106 · 2021: $125 · 2022: $406 · 2023: $827 · 2024: $343 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,889 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,889.27 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $786.25 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Acadia Pharmaceuticals INC | $603.94 | 2021-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $260.61 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $246.36 | 2023-2024 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $121.27 | 2025 | Auvelity |
| Irhythm Technologies, INC. | $119.55 | 2022 | |
| Alkermes, INC. | $97.09 | 2024 | Lybalvi |
| Astrazeneca Pharmaceuticals LP | $82.85 | 2020 | |
| Abbott Laboratories | $74.16 | 2019-2020 | |
| Inari Medical, INC. | $71.92 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heminder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.